Direkt zum Inhalt
Merck

Severe hepatitis induced by cyproterone acetate: role of corticosteroids. A case report.

Annals of hepatology (2013-01-08)
Ludovico Abenavoli, Natasa Milic, Michel Beaugrand
ZUSAMMENFASSUNG

Cyproterone acetate (CPA) is an oral anti-androgen commonly used to treat advanced prostate cancer. A variety of hepatotoxic reactions has been reported with CPA. Here we describe a case of a male patient who developed severe drug-induced hepatotoxicity during the treatment with CPA. The case, presenting sub-acute hepatitis, was characterized by a rapid evolution of cirrhosis and a protracted activity during the period of a few months despite the treatment withdrawal and an apparent benefits of corticosteroids, suggesting their indication in life threatening cases.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Ursodesoxycholsäure, ≥99%
Sigma-Aldrich
Budesonid, ≥99%
Supelco
Budesonid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Cyproteronacetat, ≥98%
Ursodesoxycholsäure, European Pharmacopoeia (EP) Reference Standard
Budesonid, European Pharmacopoeia (EP) Reference Standard
Ursodesoxycholsäure für die Systemeignung, European Pharmacopoeia (EP) Reference Standard
Cyproteronacetat, European Pharmacopoeia (EP) Reference Standard